These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 26344800)

  • 21. [Cathepsin K inhibitor: new therapy approach against osteoporosis. Pharmacological target in the osteoclast].
    Aumiller J
    MMW Fortschr Med; 2011 May; 153(19):16. PubMed ID: 21612088
    [No Abstract]   [Full Text] [Related]  

  • 22. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
    Jensen AB; Wynne C; Ramirez G; He W; Song Y; Berd Y; Wang H; Mehta A; Lombardi A
    Clin Breast Cancer; 2010 Dec; 10(6):452-8. PubMed ID: 21147688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis.
    Saag KG; de Villiers TJ; Alexandersen P; Jacobe H; Kovarik C; Werth VP; Leung A; Desai-Merchant A; Mattaliano J; Gurner D
    J Am Acad Dermatol; 2021 Apr; 84(4):1113-1119. PubMed ID: 32553680
    [No Abstract]   [Full Text] [Related]  

  • 24. Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women.
    Anderson MS; Gendrano IN; Liu C; Jeffers S; Mahon C; Mehta A; Mostoller K; Zajic S; Morris D; Lee J; Stoch SA
    J Clin Endocrinol Metab; 2014 Feb; 99(2):552-60. PubMed ID: 24276460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength.
    Cheung AM; Majumdar S; Brixen K; Chapurlat R; Fuerst T; Engelke K; Dardzinski B; Cabal A; Verbruggen N; Ather S; Rosenberg E; de Papp AE
    J Bone Miner Res; 2014 Aug; 29(8):1786-94. PubMed ID: 24643905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study.
    Duong LT; Clark S; Pickarski M; Giezek H; Cohn D; Massaad R; Stoch SA
    Osteoporos Int; 2022 Oct; 33(10):2165-2175. PubMed ID: 35711006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecule of the month. Odanacatib.
    Drug News Perspect; 2008 Jun; 21(5):281. PubMed ID: 18596992
    [No Abstract]   [Full Text] [Related]  

  • 28. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
    Eisman JA; Bone HG; Hosking DJ; McClung MR; Reid IR; Rizzoli R; Resch H; Verbruggen N; Hustad CM; DaSilva C; Petrovic R; Santora AC; Ince BA; Lombardi A
    J Bone Miner Res; 2011 Feb; 26(2):242-51. PubMed ID: 20740685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Odanacatib (MK-0822)].
    Nagase Y; Tanaka S
    Clin Calcium; 2011 Jan; 21(1):59-62. PubMed ID: 21187595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.
    Stoch SA; Zajic S; Stone J; Miller DL; Van Dyck K; Gutierrez MJ; De Decker M; Liu L; Liu Q; Scott BB; Panebianco D; Jin B; Duong LT; Gottesdiener K; Wagner JA
    Clin Pharmacol Ther; 2009 Aug; 86(2):175-82. PubMed ID: 19421185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New targets for intervention in the treatment of postmenopausal osteoporosis.
    Lewiecki EM
    Nat Rev Rheumatol; 2011 Sep; 7(11):631-8. PubMed ID: 21931340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteoporosis: now and the future.
    Rachner TD; Khosla S; Hofbauer LC
    Lancet; 2011 Apr; 377(9773):1276-87. PubMed ID: 21450337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of cathepsin K for treatment of osteoporosis.
    Boonen S; Rosenberg E; Claessens F; Vanderschueren D; Papapoulos S
    Curr Osteoporos Rep; 2012 Mar; 10(1):73-9. PubMed ID: 22228398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New therapeutical horizons in the management of postmenopausal osteoporosis.
    Migliaccio S; Fornari R; Greco EA; Di Luigi L; Lenzi A
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S117-9. PubMed ID: 24048905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence.
    Zerbini CA; McClung MR
    Ther Adv Musculoskelet Dis; 2013 Aug; 5(4):199-209. PubMed ID: 23904864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
    Muñoz-Torres M; Reyes-García R; Mezquita-Raya P; Fernández-García D; Alonso G; Luna Jde D; Ruiz-Requena ME; Escobar-Jiménez F
    Maturitas; 2009 Nov; 64(3):188-92. PubMed ID: 19819089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
    Abdelazim IA; Abdelrazak KM; Al-Kadi M; Yehia AH; Nusair BM; Faza MA
    Arch Osteoporos; 2014; 9():189. PubMed ID: 25037077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans.
    Kassahun K; McIntosh I; Koeplinger K; Sun L; Talaty JE; Miller DL; Dixon R; Zajic S; Stoch SA
    Drug Metab Dispos; 2014 May; 42(5):818-27. PubMed ID: 24553380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.